11月17日，诺和诺德、礼来股价双双走低！诺和诺德表示，从周一开始，其明星产品Wegovy和Ozempic的初始剂量每月售价为199美元。之后，诺和诺德将通过其NovoCare直销平台以每月349美元的价格提供这些药物，比目前的自费价格低30%。该价格与礼来减肥药Zepbound的售价持平，并低于高剂量的价格。此次降价旨在让诺和诺德的药物在与仿制药和礼来的Zepbound竞争时更具优势，此前诺和诺德在美国市场的领先地位已被礼来超越。
11月17日，诺和诺德、礼来股价双双走低！诺和诺德表示，从周一开始，其明星产品Wegovy和Ozempic的初始剂量每月售价为199美元。之后，诺和诺德将通过其NovoCare直销平台以每月349美元的价格提供这些药物，比目前的自费价格低30%。该价格与礼来减肥药Zepbound的售价持平，并低于高剂量的价格。此次降价旨在让诺和诺德的药物在与仿制药和礼来的Zepbound竞争时更具优势，此前诺和诺德在美国市场的领先地位已被礼来超越。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
